UNITED STATES SECURITIES AND EXCHANGE COMMISSION

~~SECURITIES~~Washington, ~~AND~~D.C. ~~EXCHANGE COMMISSION~~20549

~~Washington, DC 20549~~———————

FORM 8-K

———————

CURRENT REPORT

~~PURSUANT~~Pursuant TOto ~~SECTION~~ Section 13 ORor 15(d) OFof ~~THE~~the Securities Exchange Act of 1934

~~SECURITIES~~Date ~~EXCHANGE~~of ~~ACT~~Report OF(Date ~~1934~~of earliest event reported): December 4, 2009

~~Date of report (Date of earliest event reported): November 30, 2009~~ ———————

~~Cordex~~CORDEX ~~Pharma~~PHARMA, ~~Inc~~INC.

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Charter~~its charter)

Nevada	000-33023	86-0982792
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

———————



Nevada	000-33023	86-0982792
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

7660 Fay Avenue, Suite H-373, La Jolla, CA 92037

(Address of Principal Executive ~~Offices~~Office) (Zip Code)

~~Registrant’s telephone number, including area code:~~ (858) 551-5700

(Registrant’s telephone number, including area code)

N/A

(Former ~~Name~~name or ~~Former~~former ~~Address~~address, if ~~Changed~~changed ~~Since~~since ~~Last~~last ~~Report~~report)

~~Copies to:~~———————

~~Hank~~Check ~~Gracin,~~the ~~Esq.~~appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Lehman & Eilen, LLP

Suite 300

20283 State Route 7

Boca Raton, Florida 33498

(561) 237-0804

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item. 58.0201.

~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~Events

~~(a)~~On December 4, 2009, the Company entered into an agreement with its debenture holders which extended the maturity date of its debentures until December 15, 2009.

~~N/A~~Item 9.01.

~~(b)~~Financial Statements and Exhibits.

~~On November 30, 2009, the Company received written notice of the resignation of David Coherd as~~ (a) ~~director~~Not ~~the Company, effective immediately.~~applicable

(cb) Not applicable

~~N/A~~(c) Not applicable

(d) Exhibits.

N/A


Exhibit No.		Description
10.1		Extension to the Amendment to Debentures and Warrants, Agreement and Waiver

~~(e)-(f)~~SIGNATURES

~~N/A~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Item 9.01. Financial Statements and Exhibits.


		CORDEX PHARMA, INC.

Date:	December 10, 2009	By:	/s/ WAYNE LORGUS
			Wayne Lorgus Chief Financial Officer

(a) – (c)

N/A

(d) Exhibits.

N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORDEX PHARMA, INC. By: /s/ Dr. James Kuo Name: Title: Dr. James Kuo President and CEO

Date: November 30, 2009

Filing Compare · Cordex Pharma, Inc.